A Study Of Triple-Negative Breast Cancer Patients Tested With A 25-Gene Panel Of Hereditary Cancer Genes.

1067 Background: Although triple-negative breast cancer (TNBC) accounts for 15% to 20% of all breast cancers diagnosed in the US, its epidemiology is not well understood. Previous studies have shown a high incidence of BRCA1 and, more recently, BRCA2 mutations in patients with TNBC. As panel testing becomes more prevalent, these studies can be extended to other genes with a known breast cancer risk and improve understanding of the genetic origin of TNBC. Here we examined the gene distribution of mutations identified with a 25-gene hereditary cancer panel in patients with TNBC. Methods: We queried a commercial laboratory database for patients affected with breast cancer who were tested with a 25-gene panel of hereditary cancer genes from September 2013 through December 2014. Patients affected with TNBC were analyzed separately. All patient data was obtained by health care provider report on test requisition forms. Results: We identified 2,535 patients with a personal history of TNBC and 17,304 patients wit...